

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## **Nucleosides, Nucleotides and Nucleic Acids**

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

## **Facile Synthesis of 5-Fluorocytidine**

Minoti Sharma<sup>a</sup>; James L. Alderfer<sup>a</sup>

<sup>a</sup> Department of Biophysics, Roswell Park Memorial Institute, Buffalo, New York

**To cite this Article** Sharma, Minoti and Alderfer, James L.(1983) 'Facile Synthesis of 5-Fluorocytidine', *Nucleosides, Nucleotides and Nucleic Acids*, 2: 2, 189 — 191

**To link to this Article:** DOI: 10.1080/07328318308081258

**URL:** <http://dx.doi.org/10.1080/07328318308081258>

**PLEASE SCROLL DOWN FOR ARTICLE**

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## FACILE SYNTHESIS OF 5-FLUOROCYTIDINE

Minoti Sharma and James L. Alderfer\*

Department of Biophysics  
Roswell Park Memorial Institute, Buffalo, New York 14262

### ABSTRACT


A facile synthesis of 5-fluorocytidine, an important intermediate of various biological interests, is described in 2 steps from commercially available 5-fluorocytosine and 1-*O*-acetyl-2,3,5-tri-*O*-benzoyl- $\beta$ -D-ribofuranose.

5-Fluorocytidine (5-FCyd) is a biologically active compound which has fungistatic properties<sup>1</sup>. 5-FCyd is also found in RNA of cells<sup>2</sup> which are grown in the presence of 5-FU (5-fluorouracil), an important chemotherapeutic agent. The homopolynucleotide of 5-FCyd, poly(5-fluorocytidylic acid), forms a complex with poly(I). This polynucleotide duplex is a good interferon inducer<sup>3</sup>. In addition to the general utility of pyrimidine nucleoside analogs as antiviral and antitumor agents<sup>4</sup>, we are interested in large scale synthesis of 5-fluorocytidine, in order to convert it to various phosphorylated forms for enzymatic studies.

5-FCyd is not commercially available. The procedure reported by Robins et al.<sup>5</sup> for its synthesis includes direct fluorination of cytidine with trifluoromethyl hypofluorite. This fluorinating agent is toxic and its large scale use can be hazardous. The isolation of 5-FCyd using this procedure in our laboratory has always required preparative column or plate chromatography. Saneyoshi et al.<sup>6</sup> reported the synthesis of various 5-fluoropyrimidine nucleosides by modification of the stannic chloride catalyzed glycosylation method first introduced by Niedballa and Vorbrüggen<sup>7</sup>. This modified procedure is a definite improvement over the use of toxic hypofluorite used to synthesize 5-FCyd<sup>5</sup>. However, this procedure<sup>6</sup> involves several steps both for synthesis and isolation of pure 5-FCyd.

We wish to report in this communication the synthesis of 5-FCyd from inexpensive, commercially available 5-fluorocytosine (1) and 1-O-acetyl-2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranose (2) by the Vorbrüggen single-pot method<sup>8</sup>, without a chromatographic purification step. This procedure does not require prior synthesis of N<sub>4</sub>-acetyl-5-fluorocytosine from 5-fluorocytosine nor isolation of the silylated derivative of 5-fluorocytosine before coupling with the blocked carbohydrate, as described previously<sup>6</sup>.

The sugar-protected nucleoside (3) was synthesized by adding silylating agent (HMDS; 1.5 ml, 7 mmol) and TMCS (5.92 ml, 31 mmole) to an anhydrous suspension of (1) (1.3 g,  $\sim$ 10 mmol), (2) (5.04 g, 10 mmol) and the



\* See reference 10

catalyst, potassium nonaflate (8.12 g, 24 mmol) in acetonitrile under dry nitrogen atmosphere. The reaction mixture is refluxed for 24 hours, and is followed by silica gel TLC (methanol: chloroform, 20:80; R<sub>f</sub> (3) 0.56). After workup (3) is deblocked directly. In the reported procedure<sup>6</sup>, (3) was isolated by silica gel column chromatography as a syrup which could not be crystallized from several solvents.

The final step in nucleoside synthesis is the removal of the protecting groups. The Vorbrüggen procedure routinely treats the benzyolated nucleoside with excess methanolic ammonia for 1-3 days. This procedure failed to completely debenzoylate (3), even after 72 hours of similar treatment.

On the other hand, when the crude product, following routine workup from the condensation step, is stirred in methanol at room temperature with Amberlyst A-26 (OH<sup>-</sup>) resin<sup>7</sup>, deblocking is complete overnight (using 1 gm moist resin per gm blocked nucleoside). After workup the crude product crystallizes from water-methanol (55% yield from 5-fluorocytosine). TLC indicates the mother liquor still contains some (4). This deblocking procedure is quite simple; crystalline product (4) was obtained without the need of charcoal treatment and ion-exchange chromatography<sup>6</sup>. The crystalline product co-migrates with an authentic sample on cellulose TLC (n-butanol/H<sub>2</sub>O saturated; R<sub>F</sub>(4) 0.25). The UV spectrum and m.p. of (4) are in agreement with literature values<sup>3</sup>.

Acknowledgement: This investigation was supported by PHS Grant CA-25438, awarded by the National Cancer Institute DHHS.

#### REFERENCES

1. A. Polak and H.J. Scholer (1973). *Path. Microbiol.* 39, 148-519.
2. M.K. Gleason and H. Fraenkel-Conrat (1976). *Proc. Natl. Acad. Sci. U.S.A.* 73, 1528-1531.
3. J.O. Folayan and D.W. Hutchinson (1974). *Biochim. Biophys. Acta* 340, 194-198.
4. W.H. Prusoff and P.H. Fischer (1979). In: Nucleoside Analogues, Nato Advanced Study Institutes Series, A26, R.T. Walker, E. DeClercq and F. Eckstein, Eds., Plenum: New York, pp. 281-318.
5. M.J. Robins, M. MacCoss, S.A. Naik and G. Ramani (1976). *J. Amer. Chem. Soc.* 98, 7381-7390.
6. M. Saneyoshi, M. Inomata and F. Fukuoka (1978). *Chem. Pharm. Bull.* 26, 2990.
7. U. Niedballa and H. Vorbrüggen (1970). *Angew. Chem.* 9, 461.
8. H. Vorbrüggen and B. Bennua (1981). *Chem. Ber.* 114, 1279-1286.
9. L.A. Reed, III, P.A. Risbood and L. Goodman (1981). *J.C.S. Chem. Comm.* 760-761.
10. Abbreviations: HMDS, hexamethyldisilazane; TMCS, trimethylchlorosilane.